Global Biosimilar Bevacizuma Market Growth 2024-2030

Global Biosimilar Bevacizuma Market Growth 2024-2030

Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers. Like generics, biosimilars have similar safety and effectiveness as their original (reference) medication. But they usually cost less.

The global Biosimilar Bevacizuma market size is projected to grow from US$ 1569 million in 2024 to US$ 2692 million in 2030; it is expected to grow at a CAGR of 9.4% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Biosimilar Bevacizuma Industry Forecast” looks at past sales and reviews total world Biosimilar Bevacizuma sales in 2023, providing a comprehensive analysis by region and market sector of projected Biosimilar Bevacizuma sales for 2024 through 2030. With Biosimilar Bevacizuma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar Bevacizuma industry.

This Insight Report provides a comprehensive analysis of the global Biosimilar Bevacizuma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar Bevacizuma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar Bevacizuma market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar Bevacizuma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar Bevacizuma.

Market CAGR for biosimilar bevacizumab is being driven by the advancing product innovation. Advancing product innovation in the biosimilar bevacizumab market entails leveraging cutting-edge technologies and research methodologies to develop high-quality alternatives to the original drug. This involves refining manufacturing processes, enhancing therapeutic efficacy, and ensuring regulatory compliance. By driving innovation, companies can expand market access, improve patient outcomes, and foster competition, ultimately leading to increased affordability and accessibility of this critical biologic therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Bevacizuma market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Avastin
Mvasi
Zirabev
Aybintio
Others

Segmentation by Application:
Colorectal Cancer
Non-Small Cell Lung Cancer
Glioblastoma
Renal Cell Carcinoma
Cervical Cancer
Ovarian Cancer
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Amgen
AryoGen
Pharmed
Biothera
Boehringer Ingelheim
Centus Biotherapeutics
Henlius Biotech
Innovent Biologics
Mylan
mAbxience
Outlook Therapeutics
Pfizer
Prestige Biopharma
Roche
Samsung Bio
TOT Biopharm

Key Questions Addressed in this Report

What is the 10-year outlook for the global Biosimilar Bevacizuma market?

What factors are driving Biosimilar Bevacizuma market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Biosimilar Bevacizuma market opportunities vary by end market size?

How does Biosimilar Bevacizuma break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.